Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
05:32p CARL ICAHN : Carl Icahn acquires 'large position' in Allergan, backs..
05/26 Anacor received rival bid before Pfizer deal - filing
05/22 TEVA CFO : We'll close Allergan deal next month
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 03:54pm CEST

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ALLERGAN, INC.
05:32p CARL ICAHN : Carl Icahn acquires 'large position' in Allergan, backs CEO
05/26 Anacor received rival bid before Pfizer deal - filing
05/22 TEVA CFO : We'll close Allergan deal next month
05/22 ALLERGAN : Launches 'IBS-D on Tract,' New Online Resource to Support Patients wi..
05/18 ALLERGAN : expansion approved for $13 million city tax deal, awaits $4 million c..
05/17 PFIZER : moves on from Allergan deal collapse with new $5.2bn takeover
05/16 Pfizer buying skin drug maker Anacor for $5.2 billion
05/16 Pfizer to buy eczema drugmaker Anacor for $5.2B
05/16 ALLERGAN : Reinforces Commitment to Hypertension Management with Four Poster Pre..
05/14 TEVA PHARMACEUTICAL : Can Teva Pharmaceutical Industries Ltd (ADR) Survive Gener..
Advertisement
Income Statement Evolution
More Financials